

CLAIMS

- 1) A crystallisation process comprising:
  - a) dissolving the substance to be crystallised in a medium wherein the viscosity of the medium can be adjusted;
  - b) applying a means for adjusting the viscosity of the medium until a gel with an apparent viscosity in the range 25 to 90 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached;
  - c) allowing crystal growth;
  - d) applying a means for adjusting the viscosity of the medium until a fluid with an apparent viscosity less than 25 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached; and
  - e) harvesting the crystals.
- 20 2) A crystallisation process as claimed in claim 1, wherein the means for adjusting the viscosity of the medium is temperature change, ultrasound, thixotropicity, electro-rheology, mechanical shear, chemical additive, or pH change.
- 25 3) A crystallisation process as claimed in claim 2 wherein the means for adjusting the viscosity of the medium is pH change.
- 4) A crystallisation process as claimed in any preceding claim wherein the medium is an aqueous solution of a Carbomer.
- 30 5) A crystallisation process as claimed in claim 4, wherein the Carbomer is Carbopol 934™.

*Claim 1*

- 6) A crystallisation process as claimed in any preceding claim wherein the substance to be crystallised is a drug substance or a carrier for drug particles, suitable for use in an inhaled pharmaceutical composition.

5 7) A crystallisation process as claimed in any preceding claim wherein the substance to be crystallised is lactose, lactose monohydrate, salbutamol sulphate or ipratropium bromide.

10 8) A crystallisation process as claimed in any preceding claim, wherein the crystals are harvested by means of collection by filtration.

15 9) A crystallisation process as claimed in any preceding claim, wherein the process comprises:

20 a) dissolving the substance to be crystallised in an aqueous solution of a medium wherein the viscosity of the medium is pH-dependent;

b) adjusting the pH of the medium until a gel with an apparent viscosity in the range 25 to 90 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached;

c) allowing crystal growth;

25 d) adjusting the pH of the medium until a fluid with an apparent viscosity less than 25 Pa.s at a shear rate of  $1\text{s}^{-1}$  is reached; and

e) harvesting the crystals.

30 10) A process as claimed in claim 9 wherein the medium is an aqueous solution of a Carbomer.

11) A crystallisation process as claimed in claim 1 or 2 wherein the substance to be crystallised is fluticasone propionate or salmeterol xinafoate

- 12) Lactose monohydrate crystals obtained according to the process as claimed in any preceding claim.
- 13) Lactose monohydrate crystals as claimed in claim 12 for use in powder formulations for inhaled use.
- 5            14) Salbutamol sulphate, oxtropium bromide or ipratropium bromide crystals obtained according to the process as claimed in any of claims 1 to 10.
- 10            15) Fluticasone propionate or salmeterol xinafoate crystals obtained according to the process as claimed in claim 1 or 2.
- 15            16) Salbutamol sulphate, oxtropium bromide or ipratropium bromide crystals as claimed in claim 14 for use in powder formulations for inhaled use.
- 20            17) Fluticasone propionate or salmeterol xinafoate crystals as claimed in claim 15 for use in powder formulations for inhaled use.
- 25            18) A pharmaceutical formulation for administration by inhalation comprising lactose monohydrate crystals as claimed in claim 12 and/or salbutamol sulphate or ipratropium bromide crystals as claimed in claim 14.
- 19            18) A pharmaceutical formulation for administration by inhalation comprising lactose monohydrate crystals as claimed in claim 12 and/or fluticasone propionate or salmeterol xinafoate crystals as claimed in claim 15.

add  
B'

add  
C'

add  
D'